Overview

Aspirin Resistance and Percutaneous Coronary Intervention (PCI)

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention (PCI).
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Treatments:
Abciximab
Aspirin
Cangrelor
Clopidogrel
Eptifibatide
Krestin
polysaccharide-K
Prasugrel Hydrochloride
Ticlopidine
Tirofiban
Criteria
Inclusion Criteria:

- Age older than 18 years

- Scheduled for elective or ad-hos PCI

- Aspirin use daily for greater or equal to one week

- Aspirin resistant (ARU greater than or equal to 550 on Verify Now-ASA

Exclusion Criteria:

- Pre-procedural elevation of cardiac biomarkers (CK-MB greater or equal to 10.4ng/dl or
Tnl greater or equal to 0.4ng/dl

- administration of any GP IIb/IIIa inhibitor, anticoagulation or lytic therapy in the
previous 30 days

- Ongoing bleeding or bleeding diathesis, contraindications for anticoagulation or
increased bleeding risk or history of bleeding in the last eight weeks

- Previous stroke or transient ischemic attack or any intracranial pathology in the last
six months, major surgery or trauma within the previous six weeks

- Platelet count less than hundred thousand per cubic millimeter or hematocrit <33% or
hemoglobin <11 g per deciliter

- Subjects who received full dose low molecular weight heparin within six hours prior to
randomization

- Allergy or intolerance to any of the study drugs or the presence of any serious
comorbidity with life expectancy of ≤1year

- Scheduled for saphenous vein graft intervention, chronic total occlusions or with
impaired renal function (eGFR<60ml/min) or patients who were taking anticoagulants or
antiplatelet agents other than aspirin and clopidogrel or nonsteroidal
anti-inflammatory drugs within two weeks before the PCI procedure